Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
NCT06934655
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pediatric Obesity
- Metabolic and Bariatric Surgery
- Semaglutide
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Children's Hospital Los Angeles
- Last updated on ClinicalTrials.gov
- September 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Children's Hospital Los Angeles · Los Angeles, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.